Other new SERDs like amcenestrant (AMEERA-5, NCT04478266), camizestrant (SERENA-6, NCT04964934), giredestrant (MORPHEUS, NCT04802759), imlunestrant (EMBER-3, NCT04975308) and rintodestrant (NCT03455270) are being studied in combination with CDK4/6i in advanced HR+/HER2− metastatic BC. Here, CDK4 is linked to breast cancer.